Nasdaq · CIK 0001662774
QNCX Quince Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 23, 2026. Close $31.73 on Oct 9, 2026, +98% from the 52-week low and -96% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
QNCXOct 9, 2026 · close 31.73
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Quince Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Luca Benatti director sell | $174k 50,000 shares | -56% | - |
Transactions
The last 30 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Charles S. Ryan President | AGrant or award Employee Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jan 23, 2026 |
| Jan 23, 2026 | Dirk Thye CEO and CMO | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,000,000 | $0.00 | $0 | 1,000,000 | Jan 23, 2026 |
| Jan 23, 2026 | Brendan Hannah CBO, COO & CCO | AGrant or award Employee Stock Option (Right to Buy)derivative | -365,000 | $0.00 | $0 | 365,000 | Jan 23, 2026 |
| Jan 2, 2026 | June Bray director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,724 | $0.00 | $0 | 18,724 | Jan 21, 2026 |
| Jan 2, 2026 | David Lamond director | AGrant or award Director Stock Option (Right to Buy)derivative | +29,423 | $0.00 | $0 | 29,423 | Jan 21, 2026 |
| Jan 2, 2026 | Margaret McLoughlin director | AGrant or award Director Stock Option (Right to Buy)derivative | +19,547 | $0.00 | $0 | 19,547 | Jan 21, 2026 |
| Jan 2, 2026 | Christopher J. Senner director | AGrant or award Director Stock Option (Right to Buy)derivative | +21,810 | $0.00 | $0 | 21,810 | Jan 21, 2026 |
| Oct 23, 2024 | Luca Benatti director | JOther Common Stock | +8,918 | - | - | 89,179 | Dec 29, 2025 |
| Dec 26, 2025 | Luca Benatti director | SOpen-market sale Common Stock | -50,000 | $3.47 | $174k | 39,179 | Dec 29, 2025 |
| Dec 10, 2025 | Dirk Thye CEO and CMO | GGift Common Shares | -739,885 | $0.00 | $0 | 255,000 | Dec 12, 2025 |
| Dec 10, 2025 | Dirk Thye CEO and CMO | GGift Common Sharesindirect: Thye Trust | +739,885 | $0.00 | $0 | 739,885 | Dec 12, 2025 |
| Dec 5, 2025 | Brendan Hannah CBO, COO & CCO | MOption exercise Common Shares | +2,271 | $0.55 | $1,249 | 336,547 | Dec 8, 2025 |
| Dec 5, 2025 | Brendan Hannah CBO, COO & CCO | MOption exercise Common Shares | +25,280 | $0.94 | $24k | 361,827 | Dec 8, 2025 |
| Dec 5, 2025 | Brendan Hannah CBO, COO & CCO | MOption exercise Employee Stock Option (Right to Buy)derivative | -2,271 | $0.00 | $0 | 45,168 | Dec 8, 2025 |
| Dec 5, 2025 | Brendan Hannah CBO, COO & CCO | MOption exercise Employee Stock Option (Right to Buy)derivative | -25,280 | $0.00 | $0 | 199,720 | Dec 8, 2025 |
| Jun 18, 2025 | Brendan Hannah CBO, COO & CCO | AGrant or award Common Shares | +37,736 | $1.20 | $45k | 334,276 | Jun 23, 2025 |
| Jun 18, 2025 | Dirk Thye CEO and CMO | AGrant or award Common Shares | +150,944 | $1.20 | $181k | 994,885 | Jun 23, 2025 |
| Jun 18, 2025 | Charles S. Ryan President | AGrant or award Common Shares | +7,548 | $1.20 | $9,058 | 130,009 | Jun 23, 2025 |
| Jun 18, 2025 | Brendan Hannah CBO, COO & CCO | AGrant or award Warrantsderivative | +37,736 | $0.13 | $4,717 | 37,736 | Jun 23, 2025 |
| Jun 18, 2025 | Dirk Thye CEO and CMO | AGrant or award Warrantsderivative | +150,944 | $0.13 | $19k | 150,944 | Jun 23, 2025 |
| Jun 18, 2025 | Charles S. Ryan President | AGrant or award Warrantsderivative | +7,548 | $0.13 | $944 | 7,548 | Jun 23, 2025 |
| Jun 4, 2025 | Luca Benatti director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jun 4, 2025 | June Bray director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jun 4, 2025 | David Lamond director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jun 4, 2025 | Margaret McLoughlin director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jun 4, 2025 | Rajiv Patni director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jun 4, 2025 | Christopher J. Senner director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jun 4, 2025 | Una S Ryan director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
| Jan 28, 2025 | Brendan Hannah CBO, COO and CCO | AGrant or award Employee Stock Option (right to buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Feb 11, 2025 |
| Jan 2, 2025 | June Bray director | AGrant or award Director Stock Option (right to buy)derivative | +30,282 | $0.00 | $0 | 30,282 | Jan 8, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Luca Benattidirector
- June Braydirector
- Brendan HannahCBO, COO & CCO
- David Lamonddirector
- Margaret McLoughlindirector
- Rajiv Patnidirector, officer
- Una S Ryandirector
- Charles S. RyanPresident
- Christopher J. Sennercfo, officer, director
- Dirk ThyeCEO and CMO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.